GSK plc: Form 20-F for the period ended Dec 31, 2024
Filed with the SEC on Mar 3, 2025 and accepted by EDGAR at Mar 3, 2025, 11:03 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2024-01-01 to 2024-12-31 | GBP 31.38bn | ifrs-full:Revenue |
| Cost of revenue | 12 months2024-01-01 to 2024-12-31 | GBP 9.05bn | ifrs-full:CostOfSales |
| Gross profit | 12 months2024-01-01 to 2024-12-31 | GBP 22.33bn | ifrs-full:GrossProfit |
| Operating income | 12 months2024-01-01 to 2024-12-31 | GBP 4.02bn | ifrs-full:ProfitLossFromOperatingActivities |
| Income tax | 12 months2024-01-01 to 2024-12-31 | GBP 526.0m | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2024-01-01 to 2024-12-31 | GBP 2.58bn | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2024-01-01 to 2024-12-31 | GBP 0.62 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2024-01-01 to 2024-12-31 | GBP 0.63 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2024-01-01 to 2024-12-31 | GBP 6.55bn | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2024-01-01 to 2024-12-31 | GBP 1.40bn | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2024-12-31 | GBP 3.87bn | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2024-12-31 | GBP 17.00bn | ifrs-full:CurrentAssets |
| Total assets | At period end2024-12-31 | GBP 59.46bn | ifrs-full:Assets |
| Current liabilities | At period end2024-12-31 | GBP 21.70bn | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2024-12-31 | GBP 46.38bn | ifrs-full:Liabilities |
| Shareholders' equity | At period end2024-12-31 | GBP 13.67bn | ifrs-full:EquityAttributableToOwnersOfParent |
| Shares outstanding | At period end2024-12-31 | 4,314,303,734 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001131399-25-000007. Last ingested by Listed: Nov 6, 2026, 12:49 ET. Listed shows no prices and gives no investment advice.